Redigerer Covaxin (avsnitt)

==Kliniske forsøk==
Indian Council of Medical Researchs ''National Institute of Virology'' godkjente i mai 2020 utvikling av en indisk koronavaksine.<ref>{{cite news |title=ICMR teams up with Bharat Biotech to develop Covid-19 vaccine |url=https://www.livemint.com/news/india/icmr-teams-up-with-bharat-biotech-to-develop-covid-19-vaccine-11589038719666.html |work=Livemint |date=9. mai 2020 |}}</ref><ref>{{cite news | vauthors = Chakrabarti A |title=India to develop 'fully indigenous' Covid vaccine as ICMR partners with Bharat Biotech |url=https://theprint.in/health/india-to-develop-fully-indigenous-covid-vaccine-as-icmr-partners-with-bharat-biotech/418180/ |work=ThePrint |date=10. mai 2020}}</ref> I juni 2020 fikk selskapet tillatelse til Fase I- og Fase II-forsøk av Drugs Controller General of India. Bharat Biotech informerte i desember 2020 om resultatet av Fase I-forsøkenr.<ref>{{cite news |last1=Perappadan |first1=Bindu Shajan |title=Coronavirus {{!}} Covaxin phase-1 trial results show promising results |url=https://www.thehindu.com/sci-tech/science/coronavirus-covaxin-phase-1-trial-results-show-vaccine-is-safe/article33348040.ece |access-date=17. desember 2020 |work=The Hindu |date=16. desember 2020 |}}</ref><ref>{{cite news |last1=Sabarwal |first1=Harshit |title=Covaxin’s phase 1 trial result shows robust immune response, mild adverse events |url=https://www.hindustantimes.com/india-news/covaxin-s-phase-1-trial-result-shows-robust-immune-response-mild-adverse-events/story-0swYxDQsyoK5POHjjPO22M.html |access-date=17.desember 2020 |work=Hindustan Times |date=16. desember 2020 |language= |accessdate=2021-03-20 |archivedate=2020-12-16 |archiveurl=https://web.archive.org/web/20201216172146/https://www.hindustantimes.com/india-news/covaxin-s-phase-1-trial-result-shows-robust-immune-response-mild-adverse-events/story-0swYxDQsyoK5POHjjPO22M.html |url-status=yes }}</ref>

Bharat Biotech fikk i november 2020 tillatelse til å gjennomføre Fase III-forsøk<ref>{{cite news |title=Coronavirus {{!}} Covaxin Phase III trial from November |url=https://www.thehindu.com/business/covaxin-phase-iii-trial-from-november/article32928549.ece |work=The Hindu |date=23. oktober 2020 |language=}}</ref> etter sluttført  Fase I og Fase II. Fase III ble planlagt for omkring 26&nbsp;000 forsøkspersoner i India.<ref>{{cite news |title=Bharat Biotech begins Covaxin Phase III trials |url=https://indianexpress.com/article/india/bharat-biotech-begins-covaxin-phase-iii-trials-7055237/ |work=The Indian Express |date=18. november 2020 |language=}}</ref>